These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 33004019)

  • 21. Efficacy and Safety of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin, Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization of Patients With Diabetes Mellitus.
    Waksman R; Shlofmitz E; Windecker S; Koolen JJ; Saito S; Kandzari D; Kolm P; Lipinski MJ; Torguson R
    Am J Cardiol; 2019 Oct; 124(7):1020-1026. PubMed ID: 31353004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of efficacy and safety between ultrathin bioresorbable polymer sirolimus-eluting stents and thin durable polymer drug-eluting stents: a systematic review and meta-analysis of the literature.
    Zhai ZY; Li JX
    Coron Artery Dis; 2019 Dec; 30(8):590-599. PubMed ID: 31609756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Very early neointimal coverage of new biodegradable polymer drug-eluting stent compared with durable polymer everolimus-eluting stent evaluated by optical frequency domain imaging.
    Kobayashi N; Ito Y; Yamawaki M; Araki M; Sakai T; Sakamoto Y; Mori S; Tsutsumi M; Nauchi M; Honda Y; Tokuda T; Makino K; Shirai S; Hirano K
    Int J Cardiovasc Imaging; 2018 Apr; 34(4):515-522. PubMed ID: 29159531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thin, Very Thin, or Ultrathin Strut Biodegradable or Durable Polymer-Coated Drug-Eluting Stents: 3-Year Outcomes of BIO-RESORT.
    Buiten RA; Ploumen EH; Zocca P; Doggen CJM; Danse PW; Schotborgh CE; Scholte M; van Houwelingen KG; Stoel MG; Hartmann M; Tjon Joe Gin RM; Somi S; Linssen GCM; Kok MM; von Birgelen C
    JACC Cardiovasc Interv; 2019 Sep; 12(17):1650-1660. PubMed ID: 31422087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Everolimus-Eluting Versus Biolimus-Eluting Stents With Biodegradable Polymers in Unselected Patients Undergoing Percutaneous Coronary Intervention: A Randomized Noninferiority Trial With 1-Year Follow-Up (SORT OUT VIII Trial).
    Maeng M; Christiansen EH; Raungaard B; Kahlert J; Terkelsen CJ; Kristensen SD; Carstensen S; Aarøe J; Jensen SE; Villadsen AB; Lassen JF; Thim T; Eftekhari A; Veien KT; Hansen KN; Junker A; Bøtker HE; Jensen LO;
    JACC Cardiovasc Interv; 2019 Apr; 12(7):624-633. PubMed ID: 30947936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of patients treated with a biodegradable-polymer sirolimus-eluting stent versus durable-polymer everolimus-eluting stents after rotational atherectomy.
    Mankerious N; Hemetsberger R; Traboulsi H; Toelg R; Abdel-Wahab M; Richardt G; Allali A
    Clin Res Cardiol; 2021 Oct; 110(10):1574-1585. PubMed ID: 33861369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versus sirolimus-eluting coronary stents in patients with diabetes mellitus (the DiabeDES IV randomized angiography trial).
    Maeng M; Baranauskas A; Christiansen EH; Kaltoft A; Holm NR; Krusell LR; Ravkilde J; Tilsted HH; Thayssen P; Jensen LO
    Catheter Cardiovasc Interv; 2015 Dec; 86(7):1161-7. PubMed ID: 25640050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial.
    Franzone A; Pilgrim T; Heg D; Roffi M; Tüller D; Vuilliomenet A; Muller O; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Räber L; Stortecky S; Wenaweser P; Jüni P; Windecker S
    Circ Cardiovasc Interv; 2015 Jun; 8(6):. PubMed ID: 26043895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized comparison of novel biodegradable polymer and durable polymer-coated cobalt-chromium sirolimus-eluting stents: Three-Year Outcomes of the I-LOVE-IT 2 Trial.
    Song L; Li J; Guan C; Jing Q; Lu S; Yang L; Xu K; Yang Y; Xu B; Han Y;
    Catheter Cardiovasc Interv; 2018 Feb; 91(S1):608-616. PubMed ID: 29322619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With Diabetes Mellitus: The RESERVOIR Clinical Trial.
    Romaguera R; Gómez-Hospital JA; Gomez-Lara J; Brugaletta S; Pinar E; Jiménez-Quevedo P; Gracida M; Roura G; Ferreiro JL; Teruel L; Montanya E; Fernandez-Ortiz A; Alfonso F; Valgimigli M; Sabate M; Cequier A
    JACC Cardiovasc Interv; 2016 Jan; 9(1):42-50. PubMed ID: 26762910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in diabetic patients: Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry).
    Beneduce A; Ferrante G; Ielasi A; Pivato CA; Chiarito M; Cappelletti A; Baldetti L; Magni V; Prati E; Falcone S; Pierri A; De Martini S; Montorfano M; Parisi R; Rutigliano D; Locuratolo N; Anzuini A; Tespili M; Margonato A; Benassi A; Briguori C; Reimers B; Fabbiocchi F; Bartorelli A; Colombo A; Godino C
    Catheter Cardiovasc Interv; 2020 Aug; 96(2):255-265. PubMed ID: 31905259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 2-Year Clinical Outcomes of an Abluminal Groove-Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent.
    Xu B; Saito Y; Baumbach A; Kelbæk H; van Royen N; Zheng M; Morel MA; Knaapen P; Slagboom T; Johnson TW; Vlachojannis G; Arkenbout KE; Holmvang L; Janssens L; Ochala A; Brugaletta S; Naber CK; Anderson R; Rittger H; Berti S; Barbato E; Toth GG; Maillard L; Valina C; Buszman P; Thiele H; Schächinger V; Lansky A; Wijns W;
    JACC Cardiovasc Interv; 2019 Sep; 12(17):1679-1687. PubMed ID: 31129092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ten-year clinical outcomes of polymer-free versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus : Results of the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol- and Zotarolimus-Eluting Stents (ISAR-TEST 5) trial.
    Koch T; Lenz T; Joner M; Xhepa E; Koppara T; Wiebe J; Coughlan JJ; Aytekin A; Ibrahim T; Kessler T; Cassese S; Laugwitz KL; Schunkert H; Kastrati A; Kufner S;
    Clin Res Cardiol; 2021 Oct; 110(10):1586-1598. PubMed ID: 34156521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
    Gao RL; Xu B; Lansky AJ; Yang YJ; Ma CS; Han YL; Chen SL; Li H; Zhang RY; Fu GS; Yuan ZY; Jiang H; Huo Y; Li W; Zhang YJ; Leon MB;
    EuroIntervention; 2013 May; 9(1):75-83. PubMed ID: 23685298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of abluminal biodegradable polymer biolimus-eluting stents and durable polymer everolimus-eluting stents in the treatment of coronary bifurcations.
    Costopoulos C; Latib A; Naganuma T; Sticchi A; Ferrarello S; Regazzoli D; Chieffo A; Figini F; Carlino M; Montorfano M; Naim C; Kawaguchi M; Gerasimou A; Giannini F; Godino C; Colombo A
    Catheter Cardiovasc Interv; 2014 May; 83(6):889-95. PubMed ID: 23804318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two-year real world clinical outcomes after intravascular imaging device guided percutaneous coronary intervention with ultrathin-strut biodegradable-polymer sirolimus-eluting stent.
    Nakao S; Ishihara T; Tsujimura T; Hata Y; Higashino N; Kusuda M; Mano T
    Int J Cardiol; 2024 Mar; 399():131686. PubMed ID: 38151161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the Ultrathin Strut, Biodegradable Polymer Sirolimus-eluting Stent With a Durable Polymer Everolimus-eluting Stent in a Chinese Population: The Randomized BIOFLOW VI Trial.
    Li C; Yang Y; Han Y; Song D; Xu J; Guan C; Gao R; Garcia-Garcia HM; Waksman R; Xu B;
    Clin Ther; 2020 Apr; 42(4):649-660.e9. PubMed ID: 32268942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endothelial Barrier Protein Expression in Biodegradable Polymer Sirolimus-Eluting Versus Durable Polymer Everolimus-Eluting Metallic Stents.
    Mori H; Cheng Q; Lutter C; Smith S; Guo L; Kutyna M; Torii S; Harari E; Acampado E; Joner M; Kolodgie FD; Virmani R; Finn AV
    JACC Cardiovasc Interv; 2017 Dec; 10(23):2375-2387. PubMed ID: 29102583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Second-versus first-generation "Limus"-eluting stents in diabetic patients with coronary artery disease: a randomized comparison in setting of ISAR-TEST-4 trial.
    Kufner S; Byrne RA; Mehilli J; Massberg S; Birkmeier KA; Schulz S; Pache J; Schömig A; Kastrati A
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):E769-76. PubMed ID: 23754254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of diabetes on clinical outcomes after revascularization with sirolimus-eluting and biolimus-eluting stents with biodegradable polymer from the SORT OUT VII trial.
    Ellert J; Christiansen EH; Maeng M; Raungaard B; Jensen SE; Kristensen SD; Veien KT; Junker AB; Jakobsen L; Aarøe J; Terkelsen CJ; Kahlert J; Villadsen AB; Bøtker HE; Jensen LO
    Catheter Cardiovasc Interv; 2019 Mar; 93(4):567-573. PubMed ID: 30244533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.